The Dales Report’s Shadd Dales interviews InMed CEO, Eric A. Adams, to talk about the company’s upcoming pharmaceutical development plans for 2023.
Eric speaks about InMed’s three pharmaceutical programs:
- The most advanced program, a Phase 2 clinical trial studying cannabinol (CBN) cream for epidermolysis bullosa
- A preclinical program using a cannabinol eye drop formulation for the potential treatment of glaucoma
- The company’s most recent development program is in neurodegenerative disease.
Eric talks about InMed’s recent research of specific cannabinoid analogs showing neuroprotective effects and the potential to repair neurons, making it an interesting therapeutic target for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease.
Read the full article and watch the video on The Dales Report website.
